Skip to main content
SpringerLink
Log in

Cholestasis in the Hospitalized Patient

  • Chapter
  • First Online:
Cholestatic Liver Disease

Part of the book series: Clinical Gastroenterology ((CG))

  • 1174 Accesses

Abstract

Cholestasis results from the accumulation of bile acids within the liver, ultimately leading to hepatotoxicity. There are multiple causes of cholestasis in the hospitalized patient, and this chapter focuses on the hematopoietic stem cell transplant (HSCT) recipient. Cholestasis and jaundice are common in the setting of HSCT. The differential is broad and includes extrahepatic biliary obstruction, preexisting liver disease, cholestasis of sepsis, hemolysis, parenteral nutrition, drug-induced liver injury, graft-versus-host disease (GVHD), and sinusoidal obstruction syndrome. Additionally, cholestasis may be multifactorial in etiology. Understanding the risks and timing of cholestatic injury is crucial to its diagnosis. Preventive measures may help to minimize liver injury; however, specific treatments are lacking.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Delemos AS, Friedman LS. Systemic causes of cholestasis. Clin Liver Dis. 2013;17(2): 301–17.

    PubMed  Google Scholar 

  2. Tuncer HH, Rana N, Milani C, Darko A, Al-Homsi SA. Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. World J Gastroenterol. 2012;18(16): 1851–60.

    PubMed Central  PubMed  Google Scholar 

  3. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303(16):1617–24.

    CAS  PubMed Central  PubMed  Google Scholar 

  4. Kimoto E, Yoshida K, Balogh LM, Bi YA, Maeda K, El-Kattan AF, et al. Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. Mol Pharm. 2012;9(12):3535–42.

    CAS  PubMed  Google Scholar 

  5. Iusuf D, van de Steeg E, Schinkel AH. Functions of OATP1A and 1B transporters in vivo: insights from mouse models. Trends Pharmacol Sci. 2012;33(2):100–8.

    CAS  PubMed  Google Scholar 

  6. Vlahcevic ZR, Heuman DM, Hylemon PB. Regulation of bile acid synthesis. Hepatology. 1991;13(3):590–600.

    CAS  PubMed  Google Scholar 

  7. Moseley RH. Sepsis and cholestasis. Clin Liver Dis. 2004;8(1):83–94.

    PubMed  Google Scholar 

  8. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev. 2003;83(2):633–71.

    CAS  PubMed  Google Scholar 

  9. Pauli-Magnus C, Meier PJ. Hepatocellular transporters and cholestasis. J Clin Gastroenterol. 2005;39(4 Suppl 2):S103–10.

    PubMed  Google Scholar 

  10. Kubitz R, Droge C, Stindt J, Weissenberger K, Haussinger D. The bile salt export pump (BSEP) in health and disease. Clin Res Hepatol Gastroenterol. 2012;36(6):536–53.

    CAS  PubMed  Google Scholar 

  11. Pauli-Magnus C, Meier PJ. Hepatobiliary transporters and drug-induced cholestasis. Hepatology. 2006;44(4):778–87.

    CAS  PubMed  Google Scholar 

  12. Jansen PL, Sturm E. Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int. 2003;23(5):315–22.

    CAS  PubMed  Google Scholar 

  13. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002;123(5):1649–58.

    CAS  PubMed  Google Scholar 

  14. Noe J, Stieger B, Meier PJ. Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology. 2002;123(5):1659–66.

    CAS  PubMed  Google Scholar 

  15. Jansen PL, Muller M. The molecular genetics of familial intrahepatic cholestasis. Gut. 2000;47(1):1–5.

    CAS  PubMed Central  PubMed  Google Scholar 

  16. Keppler D. Cholestasis and the role of basolateral efflux pumps. Z Gastroenterol. 2011; 49(12):1553–7.

    CAS  PubMed  Google Scholar 

  17. Slot AJ, Molinski SV, Cole SP. Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011;50(1):179–207.

    CAS  PubMed  Google Scholar 

  18. Karpen SJ. Nuclear receptor regulation of hepatic function. J Hepatol. 2002;36(6):832–50.

    CAS  PubMed  Google Scholar 

  19. Tung CB, Tung CF, Yang DY, Hu WH, Hung DZ, Peng YC, et al. Extremely high levels of alkaline phosphatase in adult patients as a manifestation of bacteremia. Hepatogastroenterology. 2005;52(65):1347–50.

    CAS  PubMed  Google Scholar 

  20. Franson TR, LaBrecque DR, Buggy BP, Harris GJ, Hoffmann RG. Serial bilirubin determinations as a prognostic marker in clinical infections. Am J Med Sci. 1989;297(3):149–52.

    CAS  PubMed  Google Scholar 

  21. Sikuler E, Guetta V, Keynan A, Neumann L, Schlaeffer F. Abnormalities in bilirubin and liver enzyme levels in adult patients with bacteremia. A prospective study. Arch Intern Med. 1989;149(10):2246–8.

    CAS  PubMed  Google Scholar 

  22. Zimmerman HJ. Intrahepatic cholestasis. Arch Intern Med. 1979;139(9):1038–45.

    CAS  PubMed  Google Scholar 

  23. Miller DJ, Keeton DG, Webber BL, Pathol FF, Saunders SJ. Jaundice in severe bacterial infection. Gastroenterology. 1976;71(1):94–7.

    CAS  PubMed  Google Scholar 

  24. Vermillion SE, Gregg JA, Baggenstoss AH, Bartholomew LG. Jaundice associated with bacteremia. Arch Intern Med. 1969;124(5):611–8.

    CAS  PubMed  Google Scholar 

  25. Whitehead MW, Hainsworth I, Kingham JG. The causes of obvious jaundice in South West Wales: perceptions versus reality. Gut. 2001;48(3):409–13.

    CAS  PubMed Central  PubMed  Google Scholar 

  26. Ding LA, Li JS, Li YS, Zhu NT, Liu FN, Tan L. Intestinal barrier damage caused by trauma and lipopolysaccharide. World J Gastroenterol. 2004;10(16):2373–8.

    CAS  PubMed  Google Scholar 

  27. Fuchs M, Sanyal AJ. Sepsis and cholestasis. Clin Liver Dis. 2008;12(1):151–72. ix.

    PubMed  Google Scholar 

  28. Raman M, Allard JP. Parenteral nutrition related hepato-biliary disease in adults. Appl Physiol Nutr Metab. 2007;32(4):646–54.

    CAS  PubMed  Google Scholar 

  29. Gonnella PA, Helton WS, Robinson M, Wilmore DW. O-side chain of Escherichia coli endotoxin 0111:B4 is transported across the intestinal epithelium in the rat: evidence for increased transport during total parenteral nutrition. Eur J Cell Biol. 1992;59(1):224–7.

    CAS  PubMed  Google Scholar 

  30. Sturm E, Zimmerman TL, Crawford AR, Svetlov SI, Sundaram P, Ferrara JL, et al. Endotoxin-stimulated macrophages decrease bile acid uptake in WIF-B cells, a rat hepatoma hybrid cell line. Hepatology. 2000;31(1):124–30.

    CAS  PubMed  Google Scholar 

  31. Crawford JM, Boyer JL. Clinicopathology conferences: inflammation-induced cholestasis. Hepatology. 1998;28(1):253–60.

    CAS  PubMed  Google Scholar 

  32. Sakamoto S, Okanoue T, Itoh Y, Sakamoto K, Nishioji K, Nakagawa Y, et al. Intercellular adhesion molecule-1 and CD18 are involved in neutrophil adhesion and its cytotoxicity to cultured sinusoidal endothelial cells in rats. Hepatology. 1997;26(3):658–63.

    CAS  PubMed  Google Scholar 

  33. Jaeschke H. Chemokines, neutrophils, and inflammatory liver injury. Shock. 1996;6(6):403–4.

    CAS  PubMed  Google Scholar 

  34. van Oosten M, van de Bilt E, de Vries HE, van Berkel TJ, Kuiper J. Vascular adhesion molecule-1 and intercellular adhesion molecule-1 expression on rat liver cells after lipopolysaccharide administration in vivo. Hepatology. 1995;22((5):1538–46.

    PubMed  Google Scholar 

  35. Oka Y, Murata A, Nishijima J, Ogawa M, Mori T. The mechanism of hepatic cellular injury in sepsis: an in vitro study of the implications of cytokines and neutrophils in its pathogenesis. J Surg Res. 1993;55(1):1–8.

    CAS  PubMed  Google Scholar 

  36. Ayres RC, Neuberger JM, Shaw J, Joplin R, Adams DH. Intercellular adhesion molecule-1 and MHC antigens on human intrahepatic bile duct cells: effect of pro-inflammatory cytokines. Gut. 1993;34(9):1245–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  37. Trauner M, Arrese M, Soroka CJ, Ananthanarayanan M, Koeppel TA, Schlosser SF, et al. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology. 1997;113(1):255–64.

    CAS  PubMed  Google Scholar 

  38. Green RM, Beier D, Gollan JL. Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology. 1996;111(1):193–8.

    CAS  PubMed  Google Scholar 

  39. Whiting JF, Green RM, Rosenbluth AB, Gollan JL. Tumor necrosis factor-alpha decreases hepatocyte bile salt uptake and mediates endotoxin-induced cholestasis. Hepatology. 1995;22(4 Pt 1):1273–8.

    CAS  PubMed  Google Scholar 

  40. Green RM, Whiting JF, Rosenbluth AB, Beier D, Gollan JL. Interleukin-6 inhibits hepatocyte taurocholate uptake and sodium-potassium-adenosinetriphosphatase activity. Am J Physiol. 1994;267(6 Pt 1):G1094–100.

    CAS  PubMed  Google Scholar 

  41. Roelofsen H, van der Veere CN, Ottenhoff R, Schoemaker B, Jansen PL, Oude Elferink RP. Decreased bilirubin transport in the perfused liver of endotoxemic rats. Gastroenterology. 1994;107(4):1075–84.

    CAS  PubMed  Google Scholar 

  42. Wagner M, Zollner G, Trauner M. New molecular insights into the mechanisms of cholestasis. J Hepatol. 2009;51(3):565–80.

    CAS  PubMed  Google Scholar 

  43. Bolder U, Ton-Nu HT, Schteingart CD, Frick E, Hofmann AF. Hepatocyte transport of bile acids and organic anions in endotoxemic rats: impaired uptake and secretion. Gastroenterology. 1997;112(1):214–25.

    CAS  PubMed  Google Scholar 

  44. Roelofsen H, Schoemaker B, Bakker C, Ottenhoff R, Jansen PL, Elferink RP. Impaired hepatocanalicular organic anion transport in endotoxemic rats. Am J Physiol. 1995;269(3 Pt 1):G427–34.

    CAS  PubMed  Google Scholar 

  45. Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology. 2001;33(3):633–46.

    CAS  PubMed  Google Scholar 

  46. Moseley RH. Sepsis-associated jaundice. Hepatology. 1996;24(4):969–70.

    CAS  PubMed  Google Scholar 

  47. Spirli C, Nathanson MH, Fiorotto R, Duner E, Denson LA, Sanz JM, et al. Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology. 2001;121(1):156–69.

    CAS  PubMed  Google Scholar 

  48. Warskulat U, Kubitz R, Wettstein M, Stieger B, Meier PJ, Haussinger D. Regulation of bile salt export pump mRNA levels by dexamethasone and osmolarity in cultured rat hepatocytes. Biol Chem. 1999;380(11):1273–9.

    CAS  PubMed  Google Scholar 

  49. Kubitz R, Wettstein M, Warskulat U, Haussinger D. Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone. Gastroenterology. 1999;116(2):401–10.

    CAS  PubMed  Google Scholar 

  50. Garvin IP. Remarks on pneumonia biliosa. S Med Surg J. 1837;1:536.

    Google Scholar 

  51. Franson TR, Hierholzer Jr WJ, LaBrecque DR. Frequency and characteristics of hyperbilirubinemia associated with bacteremia. Rev Infect Dis. 1985;7(1):1–9.

    CAS  PubMed  Google Scholar 

  52. Phillips MJ, Poucell S, Oda M. Mechanisms of cholestasis. Lab Invest. 1986;54(6):593–608.

    CAS  PubMed  Google Scholar 

  53. Lefkowitch JH. Bile ductular cholestasis: an ominous histopathologic sign related to sepsis and “cholangitis lenta”. Hum Pathol. 1982;13(1):19–24.

    CAS  PubMed  Google Scholar 

  54. Carter BA, Karpen SJ. Intestinal failure-associated liver disease: management and treatment strategies past, present, and future. Semin Liver Dis. 2007;27(3):251–8.

    CAS  PubMed  Google Scholar 

  55. Sandhu IS, Jarvis C, Everson GT. Total parenteral nutrition and cholestasis. Clin Liver Dis. 1999;3(3):489–508. viii.

    CAS  PubMed  Google Scholar 

  56. Moss RL, Amii LA. New approaches to understanding the etiology and treatment of total parenteral nutrition-associated cholestasis. Semin Pediatr Surg. 1999;8(3):140–7.

    CAS  PubMed  Google Scholar 

  57. Balistreri WF, Bove KE. Hepatobiliary consequences of parenteral alimentation. Prog Liver Dis. 1990;9:567–601.

    CAS  PubMed  Google Scholar 

  58. Messing B, Bories C, Kunstlinger F, Bernier JJ. Does total parenteral nutrition induce gallbladder sludge formation and lithiasis? Gastroenterology. 1983;84(5 Pt 1):1012–9.

    CAS  PubMed  Google Scholar 

  59. Barbier J, Gineste D, Kraimps JL, Benand P, Carretier M, Beau P, et al. [Hepatobiliary complications of total parenteral nutrition]. Chirurgie. 1992;118(1–2):47–53.

    CAS  PubMed  Google Scholar 

  60. Nightingale JM. Hepatobiliary, renal and bone complications of intestinal failure. Best Pract Res Clin Gastroenterol. 2003;17(6):907–29.

    PubMed  Google Scholar 

  61. Kwan V, George J. Liver disease due to parenteral and enteral nutrition. Clin Liver Dis. 2004;8(4):893. x.

    CAS  PubMed  Google Scholar 

  62. Clarke PJ, Ball MJ, Kettlewell MG. Liver function tests in patients receiving parenteral nutrition. JPEN J Parenter Enteral Nutr. 1991;15(1):54–9.

    CAS  PubMed  Google Scholar 

  63. Naini BV, Lassman CR. Total parenteral nutrition therapy and liver injury: a histopathologic study with clinical correlation. Hum Pathol. 2012;43(6):826–33.

    CAS  PubMed  Google Scholar 

  64. Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med. 2000;132(7):525–32.

    CAS  PubMed  Google Scholar 

  65. Chan S, McCowen KC, Bistrian BR, Thibault A, Keane-Ellison M, Forse RA, et al. Incidence, prognosis, and etiology of end-stage liver disease in patients receiving home total parenteral nutrition. Surgery. 1999;126(1):28–34.

    CAS  PubMed  Google Scholar 

  66. Kelly DA. Liver complications of pediatric parenteral nutrition–epidemiology. Nutrition. 1998;14(1):153–7.

    CAS  PubMed  Google Scholar 

  67. Squires RH, Duggan C, Teitelbaum DH, Wales PW, Balint J, Venick R, et al. Natural history of pediatric intestinal failure: initial report from the pediatric intestinal failure consortium. J Pediatr. 2012;161(4):723–8.

    PubMed Central  PubMed  Google Scholar 

  68. Willis TC, Carter BA, Rogers SP, Hawthorne KM, Hicks PD, Abrams SA. High rates of mortality and morbidity occur in infants with parenteral nutrition-associated cholestasis. JPEN J Parenter Enteral Nutr. 2010;34(1):32–7.

    PubMed  Google Scholar 

  69. Spencer AU, Yu S, Tracy TF, Aouthmany MM, Llanos A, Brown MB, et al. Parenteral nutrition-associated cholestasis in neonates: multivariate analysis of the potential protective effect of taurine. JPEN J Parenter Enteral Nutr. 2005;29(5):337–43.

    CAS  PubMed  Google Scholar 

  70. Andorsky DJ, Lund DP, Lillehei CW, Jaksic T, Dicanzio J, Richardson DS, et al. Nutritional and other postoperative management of neonates with short bowel syndrome correlates with clinical outcomes. J Pediatr. 2001;139(1):27–33.

    CAS  PubMed  Google Scholar 

  71. Beath SV, Davies P, Papadopoulou A, Khan AR, Buick RG, Corkery JJ, et al. Parenteral nutrition-related cholestasis in postsurgical neonates: multivariate analysis of risk factors. J Pediatr Surg. 1996;31(4):604–6.

    CAS  PubMed  Google Scholar 

  72. Moss RL, Amii LA. New approaches to understanding the etiology and treatment of total parenteral nutrition-associated cholestasis. Semin Pediatr Surg. 1999;8(3):140–7.

    CAS  PubMed  Google Scholar 

  73. Fein BI, Holt PR. Hepatobiliary complications of total parenteral nutrition. J Clin Gastroenterol. 1994;18(1):62–6.

    CAS  PubMed  Google Scholar 

  74. Campos AC, Oler A, Meguid MM, Chen TY. Liver biochemical and histological changes with graded amounts of total parenteral nutrition. Arch Surg. 1990;125(4):447–50.

    CAS  PubMed  Google Scholar 

  75. Meguid MM, Chen TY, Yang ZJ, Campos AC, Hitch DC, Gleason JR. Effects of continuous graded total parenteral nutrition on feeding indexes and metabolic concomitants in rats. Am J Physiol. 1991;260(1 Pt 1):E126–40.

    CAS  PubMed  Google Scholar 

  76. Li S, Nussbaum MS, Teague D, Gapen CL, Dayal R, Fischer JE. Increasing dextrose concentrations in total parenteral nutrition (TPN) causes alterations in hepatic morphology and plasma levels of insulin and glucagon in rats. J Surg Res. 1988;44(6):639–48.

    CAS  PubMed  Google Scholar 

  77. Kaminski DL, Adams A, Jellinek M. The effect of hyperalimentation on hepatic lipid content and lipogenic enzyme activity in rats and man. Surgery. 1980;88(1):93–100.

    CAS  PubMed  Google Scholar 

  78. Premkumar MH, Carter BA, Hawthorne KM, King K, Abrams SA. High rates of resolution of cholestasis in parenteral nutrition-associated liver disease with fish oil-based lipid emulsion monotherapy. J Pediatr. 2013;162(4):793–8.

    CAS  PubMed  Google Scholar 

  79. Ellegard L, Sunesson A, Bosaeus I. High serum phytosterol levels in short bowel patients on parenteral nutrition support. Clin Nutr. 2005;24(3):415–20.

    CAS  PubMed  Google Scholar 

  80. Iyer KR, Spitz L, Clayton P. BAPS prize lecture: new insight into mechanisms of parenteral nutrition-associated cholestasis: role of plant sterols. British association of paediatric surgeons. J Pediatr Surg. 1998;33(1):1–6.

    CAS  PubMed  Google Scholar 

  81. Clayton PT, Bowron A, Mills KA, Massoud A, Casteels M, Milla PJ. Phytosterolemia in children with parenteral nutrition-associated cholestatic liver disease. Gastroenterology. 1993;105(6):1806–13.

    CAS  PubMed  Google Scholar 

  82. Matilla B, Ortiz J, Gonzalez P, Garcia-Diez F, Jorquera F, Culebras JM, et al. Effects of parenteral nutrition supplemented with glutamine or glutamine dipeptides on liver antioxidant and detoxication systems in rats. Nutrition. 2000;16(2):125–8.

    CAS  PubMed  Google Scholar 

  83. Sokol RJ, Taylor SF, Devereaux MW, Khandwala R, Sondheimer NJ, Shikes RH, et al. Hepatic oxidant injury and glutathione depletion during total parenteral nutrition in weanling rats. Am J Physiol. 1996;270(4 Pt 1):G691–700.

    CAS  PubMed  Google Scholar 

  84. Chessex P, Lavoie JC, Laborie S, Rouleau T. Parenteral multivitamin supplementation induces both oxidant and antioxidant responses in the liver of newborn guinea pigs. J Pediatr Gastroenterol Nutr. 2001;32(3):316–21.

    CAS  PubMed  Google Scholar 

  85. Cai W, Wu J, Hong L, Xu Y, Tang Q, Shi C. Oxidative injury and hepatocyte apoptosis in total parenteral nutrition-associated liver dysfunction. J Pediatr Surg. 2006;41(10):1663–8.

    PubMed  Google Scholar 

  86. Wu J, Tang Q, Feng Y, Huang J, Tao Y, Wang Y, et al. Nutrition assessment in children with short bowel syndrome weaned off parenteral nutrition: a long-term follow-up study. J Pediatr Surg. 2007;42(8):1372–6.

    PubMed  Google Scholar 

  87. Buchman AL, Ament ME, Sohel M, Dubin M, Jenden DJ, Roch M, et al. Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: proof of a human choline requirement: a placebo-controlled trial. JPEN J Parenter Enteral Nutr. 2001;25(5):260–8.

    CAS  PubMed  Google Scholar 

  88. Misra S, Ament ME, Vargas JH, Skoff C, Reyen L, Herzog F. Chronic liver disease in children on long-term parenteral nutrition. J Gastroenterol Hepatol. 1996;11(5):S4–6.

    CAS  PubMed  Google Scholar 

  89. Hwang TL, Lue MC, Chen LL. Early use of cyclic TPN prevents further deterioration of liver functions for the TPN patients with impaired liver function. Hepatogastroenterology. 2000;47(35):1347–50.

    CAS  PubMed  Google Scholar 

  90. Trauner M, Wagner M, Fickert P, Zollner G. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J Clin Gastroenterol. 2005;39(4 Suppl 2):S111–24.

    PubMed  Google Scholar 

  91. Chen CY, Tsao PN, Chen HL, Chou HC, Hsieh WS, Chang MH. Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis. J Pediatr. 2004;145(3):317–21.

    CAS  PubMed  Google Scholar 

  92. Kumar D, Tandon RK. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol. 2001;16(1):3–14.

    CAS  PubMed  Google Scholar 

  93. Sugatani J. Function, genetic polymorphism, and transcriptional regulation of human UDP-glucuronosyltransferase (UGT) 1A1. Drug Metab Pharmacokinet. 2012;28:83–92.

    PubMed  Google Scholar 

  94. Park K, Williams DP, Naisbitt DJ, Kitteringham NR, Pirmohamed M. Investigation of toxic metabolites during drug development. Toxicol Appl Pharmacol. 2005;207(2 Suppl):425–34.

    PubMed  Google Scholar 

  95. Park BK, Pirmohamed M, Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther. 1995;68(3):385–424.

    CAS  PubMed  Google Scholar 

  96. Gunawan BK, Kaplowitz N. Mechanisms of drug-induced liver disease. Clin Liver Dis. 2007;11(3):459–75. v.

    PubMed  Google Scholar 

  97. Possuelo LG, Castelan JA, de Brito TC, Ribeiro AW, Cafrune PI, Picon PD, et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol. 2008;64(7):673–81.

    CAS  PubMed  Google Scholar 

  98. Leiro V, Fernandez-Villar A, Valverde D, Constenla L, Vazquez R, Pineiro L, et al. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int. 2008;28(6):835–9.

    CAS  PubMed  Google Scholar 

  99. Lucena MI, Andrade RJ, Martinez C, Ulzurrun E, Garcia-Martin E, Borraz Y, et al. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology. 2008;48(2):588–96.

    PubMed  Google Scholar 

  100. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007;132(1):272–81.

    CAS  PubMed  Google Scholar 

  101. Choi JH, Ahn BM, Yi J, Lee JH, Lee JH, Nam SW, et al. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics. 2007;17(6):403–15.

    CAS  PubMed  Google Scholar 

  102. Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics. 2007;17(1):47–60.

    CAS  PubMed  Google Scholar 

  103. Cho HJ, Koh WJ, Ryu YJ, Ki CS, Nam MH, Kim JW, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb). 2007;87(6):551–6.

    CAS  Google Scholar 

  104. Roy B, Chowdhury A, Kundu S, Santra A, Dey B, Chakraborty M, et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol. 2001;16(9):1033–7.

    CAS  PubMed  Google Scholar 

  105. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis. 2000;4(3):256–61.

    CAS  PubMed  Google Scholar 

  106. Werck-Reichhart D, Feyereisen R. Cytochromes P450: a success story. Genome Biol. 2000;1(6):REVIEWS3003.

    CAS  PubMed Central  PubMed  Google Scholar 

  107. Peterson JA, Graham SE. A close family resemblance: the importance of structure in understanding cytochromes P450. Structure. 1998;6(9):1079–85.

    CAS  PubMed  Google Scholar 

  108. Smith G, Stubbins MJ, Harries LW, Wolf CR. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica. 1998;28(12):1129–65.

    CAS  PubMed  Google Scholar 

  109. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996;6(1):1–42.

    CAS  PubMed  Google Scholar 

  110. Gonzalez FJ. Molecular genetics of the P-450 superfamily. Pharmacol Ther. 1990;45(1): 1–38.

    CAS  PubMed  Google Scholar 

  111. Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab. 2002;3(6):561–97.

    CAS  PubMed  Google Scholar 

  112. Lehmann DE. Enzymatic shunting: resolving the acetaminophen-warfarin controversy. Pharmacotherapy. 2000;20(12):1464–8.

    CAS  PubMed  Google Scholar 

  113. Ehrenpreis ED, Ehrenpreis S. Cytochrome P450: role in drug-induced hepatotoxicity. Clin Liver Dis. 1998;2:457.

    Google Scholar 

  114. Wrighton SA, Vandenbranden M, Ring BJ. The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm. 1996;24(5):461–73.

    CAS  PubMed  Google Scholar 

  115. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm. 1996;24(5):475–90.

    CAS  PubMed  Google Scholar 

  116. Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol. 1995;15(6):387–98.

    CAS  PubMed  Google Scholar 

  117. Watkins PB. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am. 1992;21(3):511–26.

    CAS  PubMed  Google Scholar 

  118. Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys. 1999;369(1):11–23.

    CAS  PubMed  Google Scholar 

  119. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther. 2005;78(3):260–77.

    CAS  PubMed  Google Scholar 

  120. Murray M. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (review). Int J Mol Med. 1999;3(3):227–38.

    CAS  PubMed  Google Scholar 

  121. Bjornsson ES, Jonasson JG. Drug-induced cholestasis. Clin Liver Dis. 2013;17(2):191–209.

    PubMed  Google Scholar 

  122. Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. Hepatology. 2011;53(4):1377–87.

    CAS  PubMed Central  PubMed  Google Scholar 

  123. Bjornsson E, Ismael S, Nejdet S, Kilander A. Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis. Scand J Gastroenterol. 2003;38(1): 86–94.

    CAS  PubMed  Google Scholar 

  124. Malchow-Moller A, Matzen P, Bjerregaard B, Hilden J, Holst-Christensen J, Staehr JT, et al. Causes and characteristics of 500 consecutive cases of jaundice. Scand J Gastroenterol. 1981;16(1):1–6.

    CAS  PubMed  Google Scholar 

  125. Bjorneboe M, Iversen O, Olsen S. Infective hepatitis and toxic jaundice in a municipal hospital during a five-year period. Incidence and prognosis. Acta Med Scand. 1967;182(4):491–501.

    CAS  PubMed  Google Scholar 

  126. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924–34. 1934.

    PubMed Central  PubMed  Google Scholar 

  127. Bohan A, Boyer JL. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin Liver Dis. 2002;22(2):123–36.

    CAS  PubMed  Google Scholar 

  128. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451–5.

    PubMed  Google Scholar 

  129. Lucena MI, Andrade RJ, Kaplowitz N, Garcia-Cortes M, Fernandez MC, Romero-Gomez M, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 2009;49(6):2001–9.

    PubMed  Google Scholar 

  130. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47(6):2003–9.

    CAS  PubMed  Google Scholar 

  131. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology. 2010;51(2):615–20.

    CAS  PubMed  Google Scholar 

  132. Bjornsson E. Drug-induced liver injury: Hy’s rule revisited. Clin Pharmacol Ther. 2006;79(6):521–8.

    PubMed  Google Scholar 

  133. Reuben A. Hy’s law. Hepatology. 2004;39(2):574–8.

    PubMed  Google Scholar 

  134. Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138(7):2246–59.

    CAS  PubMed Central  PubMed  Google Scholar 

  135. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42(2):481–9.

    PubMed  Google Scholar 

  136. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–21.

    PubMed  Google Scholar 

  137. Andrade RJ, Lucena MI, Alonso A, Garcia-Cortes M, Garcia-Ruiz E, Benitez R, et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology. 2004;39(6):1603–12.

    CAS  PubMed  Google Scholar 

  138. Hautekeete ML, Horsmans Y, Van WC, Demanet C, Henrion J, Verbist L, et al. HLA association of amoxicillin-clavulanate–induced hepatitis. Gastroenterology. 1999;117(5):1181–6.

    CAS  PubMed  Google Scholar 

  139. Maggio MC, Liotta A, Cardella F, Corsello G. Stevens-Johnson syndrome and cholestatic hepatitis induced by acute Epstein-Barr virus infection. Eur J Gastroenterol Hepatol. 2011;23(3):289.

    PubMed  Google Scholar 

  140. Ratnayake EC, Shivanthan C, Wijesiriwardena BC. Cholestatic hepatitis in a patient with typhoid fever—a case report. Ann Clin Microbiol Antimicrob. 2011;10:35.

    PubMed Central  PubMed  Google Scholar 

  141. Choi HC, Lee SH, Kim J, Kim SH, Hwang JH, Kim JW, et al. A case of acute q Fever with severe acute cholestatic hepatitis. Gut Liver. 2009;3(2):141–4.

    PubMed Central  PubMed  Google Scholar 

  142. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs–II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46(11):1331–6.

    CAS  PubMed  Google Scholar 

  143. USFDA. Guidance for industry drug-induced liver injury: premarketing clinical evaluation. 2007. Ref type: online source.

    Google Scholar 

  144. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology. 2001;33(1):308–10.

    CAS  PubMed  Google Scholar 

  145. Danan G, Benichou C. Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323–30.

    CAS  PubMed  Google Scholar 

  146. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731–9.

    CAS  PubMed  Google Scholar 

  147. Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis. 2009;29(4): 364–72.

    PubMed  Google Scholar 

  148. Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54(3):931–9.

    PubMed Central  PubMed  Google Scholar 

  149. Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, et al. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology. 1994;20(6):1437–41.

    CAS  PubMed  Google Scholar 

  150. Andrade RJ, Lucena MI, Kaplowitz N, Garcia-Munoz B, Borraz Y, Pachkoria K, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology. 2006;44(6):1581–8.

    CAS  PubMed  Google Scholar 

  151. Noronha V, Shafi NQ, Obando JA, Kummar S. Primary non-Hodgkin’s lymphoma of the liver. Crit Rev Oncol Hematol. 2005;53(3):199–207.

    PubMed  Google Scholar 

  152. Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36–41.

    CAS  PubMed  Google Scholar 

  153. Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant. 2013;13 Suppl 3:41–54.

    CAS  PubMed  Google Scholar 

  154. Rasche L, Kapp M, Einsele H, Mielke S. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT. Bone Marrow Transplant. 2013;49:163–7.

    PubMed  Google Scholar 

  155. Dignan FL, Scarisbrick JJ, Cornish J, Clark A, Amrolia P, Jackson G, et al. Organ-specific management and supportive care in chronic graft-versus-host disease. Br J Haematol. 2012;158(1):62–78.

    CAS  PubMed  Google Scholar 

  156. Chen GL, Zhang Y, Hahn T, Abrams S, Ross M, Liu H, et al. Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning. Bone Marrow Transplant. 2013;49:248–53.

    PubMed  Google Scholar 

  157. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550–61.

    CAS  PubMed Central  PubMed  Google Scholar 

  158. Strasser SI, Shulman HM, McDonald GB. Cholestasis after hematopoietic cell transplantation. Clin Liver Dis. 1999;3(3):651–68. x.

    CAS  PubMed  Google Scholar 

  159. Shulman HM, Sharma P, Amos D, Fenster LF, McDonald GB. A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology. 1988;8(3):463–70.

    CAS  PubMed  Google Scholar 

  160. Snover DC. Acute and chronic graft versus host disease: histopathological evidence for two distinct pathogenetic mechanisms. Hum Pathol. 1984;15(3):202–5.

    CAS  PubMed  Google Scholar 

  161. Akpek G, Boitnott JK, Lee LA, Hallick JP, Torbenson M, Jacobsohn DA, et al. Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood. 2002;100(12):3903–7.

    CAS  PubMed  Google Scholar 

  162. Fujii N, Takenaka K, Shinagawa K, Ikeda K, Maeda Y, Sunami K, et al. Hepatic graft-versus-host disease presenting as an acute hepatitis after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001;27(9):1007–10.

    CAS  PubMed  Google Scholar 

  163. Strasser SI, Shulman HM, Flowers ME, Reddy R, Margolis DA, Prumbaum M, et al. Chronic graft-versus-host disease of the liver: presentation as an acute hepatitis. Hepatology. 2000;32(6):1265–71.

    CAS  PubMed  Google Scholar 

  164. Gooley TA, Rajvanshi P, Schoch HG, McDonald GB. Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. Hepatology. 2005;41(2): 345–52.

    CAS  PubMed  Google Scholar 

  165. Dignan FL, Amrolia P, Clark A, Cornish J, Jackson G, Mahendra P, et al. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol. 2012;158(1):46–61.

    CAS  PubMed  Google Scholar 

  166. Hashmi K. Graft versus host disease. J Pak Med Assoc. 2005;55(11):467–8.

    PubMed  Google Scholar 

  167. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–8.

    CAS  PubMed  Google Scholar 

  168. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–56.

    PubMed  Google Scholar 

  169. Greinix HT, Loddenkemper C, Pavletic SZ, Holler E, Socie G, Lawitschka A, et al. Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. Biol Blood Marrow Transplant. 2011;17(2):167–75.

    PubMed  Google Scholar 

  170. Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ, et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007;109(7):3108–14.

    CAS  PubMed Central  PubMed  Google Scholar 

  171. Tay J, Tinmouth A, Fergusson D, Huebsch L, Allan DS. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(2):206–17.

    CAS  PubMed  Google Scholar 

  172. Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood. 2002;100(6):1977–83.

    CAS  PubMed  Google Scholar 

  173. Marks C, Stadler M, Hausermann P, Wolff D, Buchholz S, Stary G, et al. German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GVHD): guidance for supportive therapy of chronic cutaneous and musculoskeletal GVHD. Br J Dermatol. 2011;165(1):18–29.

    CAS  PubMed  Google Scholar 

  174. Landfried K, Wolff D, Holler E. Pathophysiology and management of graft-versus-host disease in the era of reduced-intensity conditioning. Curr Opin Oncol. 2009;21 Suppl 1:S39–41.

    PubMed  Google Scholar 

  175. Deeg HJ. How I, treat refractory acute GVHD. Blood. 2007;109(10):4119–26.

    CAS  PubMed Central  PubMed  Google Scholar 

  176. Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C, et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood. 2007;109(7):2751–8.

    CAS  PubMed  Google Scholar 

  177. MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant. 2002;8(7):387–94.

    CAS  PubMed  Google Scholar 

  178. Pidala J. Graft-vs-host disease following allogeneic hematopoietic cell transplantation. Cancer Control. 2011;18(4):268–76.

    PubMed  Google Scholar 

  179. Greinix HT, Knobler RM, Worel N, Schneider B, Schneeberger A, Hoecker P, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica. 2006;91(3):405–8.

    PubMed  Google Scholar 

  180. Dall’Amico R, Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher. 2002;6(4):296–304.

    PubMed  Google Scholar 

  181. Willmot F, Robertson G. Senecio disease, or cirrhosis of the liver due to senecio poisoning. Lancet. 1920;196(5069):848–9.

    Google Scholar 

  182. Jacobs P, Miller JL, Uys CJ, Dietrich BE. Fatal veno-occlusive disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukaemia. S Afr Med J. 1979;55(1):5–10.

    CAS  PubMed  Google Scholar 

  183. Berk PD, Popper H, Krueger GR, Decter J, Herzig G, Graw Jr RG. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation: possible association with graft-versus-host disease. Ann Intern Med. 1979;90(2):158–64.

    CAS  PubMed  Google Scholar 

  184. Kumar S, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc. 2003;78(5):589–98.

    PubMed  Google Scholar 

  185. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22(1):27–42.

    PubMed  Google Scholar 

  186. Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16(2):157–68.

    PubMed Central  PubMed  Google Scholar 

  187. Hogan WJ, Maris M, Storer B, Sandmaier BM, Maloney DG, Schoch HG, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood. 2004;103(1):78–84.

    CAS  PubMed  Google Scholar 

  188. Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood. 1998;92(10):3599–604.

    CAS  PubMed  Google Scholar 

  189. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease–liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant. 1992;10(3):197–214.

    CAS  PubMed  Google Scholar 

  190. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44(6):778–83.

    CAS  PubMed  Google Scholar 

  191. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4(1):116–22.

    CAS  PubMed  Google Scholar 

  192. Levitsky J, Sorrell MF. Hepatic complications of hematopoietic cell transplantation. Curr Gastroenterol Rep. 2007;9(1):60–5.

    PubMed  Google Scholar 

  193. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 1995;85(11):3005–20.

    CAS  PubMed  Google Scholar 

  194. Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology. 1994;19(5):1171–81.

    CAS  PubMed  Google Scholar 

  195. Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol. 1987;127(3):549–58.

    CAS  PubMed Central  PubMed  Google Scholar 

  196. Shulman HM, McDonald GB, Matthews D, Doney KC, Kopecky KJ, Gauvreau JM, et al. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology. 1980;79(6):1178–91.

    CAS  PubMed  Google Scholar 

  197. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le CM, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15(3):460–6.

    CAS  PubMed  Google Scholar 

  198. Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010;56(4):430–9.

    PubMed  Google Scholar 

  199. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology. 2009;49(5):1729–64.

    CAS  PubMed  Google Scholar 

  200. DeLeve LD. Hepatic microvasculature in liver injury. Semin Liver Dis. 2007;27(4): 390–400.

    CAS  PubMed  Google Scholar 

  201. McCuskey RS. Morphological mechanisms for regulating blood flow through hepatic sinusoids. Liver. 2000;20(1):3–7.

    CAS  PubMed  Google Scholar 

  202. McCuskey RS, Reilly FD. Hepatic microvasculature: dynamic structure and its regulation. Semin Liver Dis. 1993;13(1):1–12.

    CAS  PubMed  Google Scholar 

  203. Cutler C, Kim HT, Ayanian S, Bradwin G, Revta C, Aldridge J, et al. Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant. 2010;16(8):1180–5.

    CAS  PubMed Central  PubMed  Google Scholar 

  204. Rubbia-Brandt L. Sinusoidal obstruction syndrome. Clin Liver Dis. 2010;14(4):651–68.

    PubMed  Google Scholar 

  205. Hubert C, Sempoux C, Horsmans Y, Rahier J, Humblet Y, Machiels JP, et al. Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? Liver Int. 2007;27(7):938–43.

    CAS  PubMed  Google Scholar 

  206. Aloia T, Sebagh M, Plasse M, Karam V, Levi F, Giacchetti S, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24(31):4983–90.

    CAS  PubMed  Google Scholar 

  207. Faioni EM, Mannucci PM. Venocclusive disease of the liver after bone marrow transplantation: the role of hemostasis. Leuk Lymphoma. 1997;25(3–4):233–45.

    CAS  PubMed  Google Scholar 

  208. Faioni EM, Krachmalnicoff A, Bearman SI, Federici AB, Decarli A, Gianni AM, et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. Blood. 1993;81(12):3458–62.

    CAS  PubMed  Google Scholar 

  209. Scrobohaci ML, Drouet L, Monem-Mansi A, Devergie A, Baudin B, D'Agay MF, et al. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res. 1991;63(5):509–19.

    CAS  PubMed  Google Scholar 

  210. Harper PL, Jarvis J, Jennings I, Luddington R, Marcus RE. Changes in the natural anticoagulants following bone marrow transplantation. Bone Marrow Transplant. 1990;5(1):39–42.

    CAS  PubMed  Google Scholar 

  211. Vannucchi AM, Rafanelli D, Longo G, Bosi A, Guidi S, Saccardi R, et al. Early hemostatic alterations following bone marrow transplantation: a prospective study. Haematologica. 1994;79(6):519–25.

    CAS  PubMed  Google Scholar 

  212. Catani L, Gugliotta L, Mattioli BM, Vianelli N, Gherlinzoni F, Miggiano MC, et al. Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies. Bone Marrow Transplant. 1993;12(3):253–9.

    CAS  PubMed  Google Scholar 

  213. Collins PW, Gutteridge CN, O’Driscoll A, Blair S, Jones L, Aitchison R, et al. von Willebrand factor as a marker of endothelial cell activation following BMT. Bone Marrow Transplant. 1992;10(6):499–506.

    CAS  PubMed  Google Scholar 

  214. Vollmar B, Menger MD. The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. Physiol Rev. 2009;89(4):1269–339.

    CAS  PubMed  Google Scholar 

  215. McCuskey RS. Sinusoidal endothelial cells as an early target for hepatic toxicants. Clin Hemorheol Microcirc. 2006;34(1–2):5–10.

    CAS  PubMed  Google Scholar 

  216. Ho VT, Cutler C. Current and novel therapies in acute GVHD. Best Pract Res Clin Haematol. 2008;21(2):223–37.

    CAS  PubMed  Google Scholar 

  217. McCune JS, Batchelder A, Deeg HJ, Gooley T, Cole S, Phillips B, et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant. 2007;13(7): 853–62.

    CAS  PubMed  Google Scholar 

  218. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003;101(5):2043–8.

    CAS  PubMed  Google Scholar 

  219. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92(2):406–13.

    CAS  PubMed  Google Scholar 

  220. Hagglund H, Remberger M, Klaesson S, Lonnqvist B, Ljungman P, Ringden O. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood. 1998;92(12):4568–72.

    CAS  PubMed  Google Scholar 

  221. Rozman C, Carreras E, Qian C, Gale RP, Bortin MM, Rowlings PA, et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant. 1996;17(1):75–80.

    CAS  PubMed  Google Scholar 

  222. Frickhofen N, Wiesneth M, Jainta C, Hertenstein B, Heymer B, Bianchi L, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood. 1994;83(7):1998–2004.

    CAS  PubMed  Google Scholar 

  223. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118(4):255–67.

    CAS  PubMed  Google Scholar 

  224. Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, et al. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol. 1990;8(10):1699–706.

    CAS  PubMed  Google Scholar 

  225. DeLeve LD, Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology. 2000;60(3):143–54.

    CAS  PubMed  Google Scholar 

  226. DeLeve LD. Glutathione defense in non-parenchymal cells. Semin Liver Dis. 1998;18(4):403–13.

    CAS  PubMed  Google Scholar 

  227. DeLeve LD, Kaplowitz N. Importance and regulation of hepatic glutathione. Semin Liver Dis. 1990;10(4):251–66.

    CAS  PubMed  Google Scholar 

  228. Teicher BA, Crawford JM, Holden SA, Lin Y, Cathcart KN, Luchette CA, et al. Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide. Cancer. 1988;62(7):1275–81.

    CAS  PubMed  Google Scholar 

  229. DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology. 1996;24(4):830–7.

    CAS  PubMed  Google Scholar 

  230. Deeg HJ, Sullivan KM, Buckner CD, Storb R, Appelbaum FR, Clift RA, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. Bone Marrow Transplant. 1986;1(2):151–7.

    CAS  PubMed  Google Scholar 

  231. Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol. 2000;64(5):281–91.

    CAS  PubMed  Google Scholar 

  232. Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood. 1994;83(9):2723–30.

    CAS  PubMed  Google Scholar 

  233. Meresse V, Hartmann O, Vassal G, Benhamou E, Valteau-Couanet D, Brugieres L, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant. 1992;10(2):135–41.

    CAS  PubMed  Google Scholar 

  234. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol. 1993;20(4 Suppl 4):18–25.

    CAS  PubMed  Google Scholar 

  235. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25(1):55–61.

    CAS  PubMed  Google Scholar 

  236. McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM, et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007;31(5):599–604.

    CAS  PubMed  Google Scholar 

  237. Rio B, Andreu G, Nicod A, Arrago JP, Dutrillaux F, Samama M, et al. Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy. Blood. 1986;67(6):1773–6.

    CAS  PubMed  Google Scholar 

  238. Lassau N, Leclere J, Auperin A, Bourhis JH, Hartmann O, Valteau-Couanet D, et al. Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients. Radiology. 1997;204(2):545–52.

    CAS  PubMed  Google Scholar 

  239. Shulman HM, Gooley T, Dudley MD, Kofler T, Feldman R, Dwyer D, et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation. 1995;59(7):1015–22.

    CAS  PubMed  Google Scholar 

  240. Carreras E, Granena A, Navasa M, Bruguera M, Marco V, Sierra J, et al. Transjugular liver biopsy in BMT. Bone Marrow Transplant. 1993;11(1):21–6.

    CAS  PubMed  Google Scholar 

  241. Richardson PG, Ho VT, Giralt S, Arai S, Mineishi S, Cutler C, et al. Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. Ther Adv Hematol. 2012;3(4):253–65.

    CAS  PubMed Central  PubMed  Google Scholar 

  242. Zhang L, Wang Y, Huang H. Defibrotide for the prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review. Clin Transplant. 2012;26(4):511–9.

    CAS  PubMed  Google Scholar 

  243. Haussmann U, Fischer J, Eber S, Scherer F, Seger R, Gungor T. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica. 2006;91(6):795–800.

    PubMed  Google Scholar 

  244. Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood. 1997;89(5):1501–6.

    CAS  PubMed  Google Scholar 

  245. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92(3):737–44.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Swedish Liver Center, Swedish Health Systems, 1101 Madison Street #200, Seattle, WA, 98104, USA

    Anne M. Larson M.D.

Authors
  1. Anne M. Larson M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne M. Larson M.D. .

Editor information

Editors and Affiliations

  1. Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona, USA

    Elizabeth J. Carey

  2. Mayo Clinic, Phoenix, Arizona, USA

    Keith D. Lindor

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Larson, A.M. (2014). Cholestasis in the Hospitalized Patient. In: Carey, E., Lindor, K. (eds) Cholestatic Liver Disease. Clinical Gastroenterology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1013-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1013-7_11

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-1012-0

  • Online ISBN: 978-1-4939-1013-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation